Core Viewpoint - The recent adjustments to the artificial cochlear implant reimbursement policy aim to enhance the efficiency of medical insurance fund usage while ensuring basic medical security for patients [1][2]. Group 1: Policy Adjustments - The new policy states that cochlear implants not officially registered in China will no longer be covered by basic medical insurance in Hainan Province starting January 9, 2026 [1]. - Patients who have already been hospitalized before January 8, 2026, will continue to receive insurance benefits under the previous policy, ensuring their rights are protected [1]. Group 2: Coverage Criteria - The policy specifies strict eligibility criteria for insurance coverage, including: - For pre-lingual deaf patients: children under 7 years with severe to profound sensorineural hearing loss, or those under 18 with some speech foundation after rehabilitation [2]. - For post-lingual deaf patients: individuals with severe to profound hearing loss who cannot communicate normally even with hearing aids [2]. Group 3: Payment Standardization - The reimbursement policy has been standardized for urban and rural residents, aligning the maximum payment limits for cochlear implant consumables [2]. - The reimbursement will be based on the winning bid prices from national procurement for cochlear implants, with non-winning products capped at the highest winning price for similar products [2]. Group 4: Service Classification - Two key medical services related to cochlear implants have been reclassified from Category C to Category B, allowing for a higher reimbursement rate from the insurance fund [3].

Group 1 - The Sichuan Provincial Medical Security Bureau has officially included cochlear implantation surgery and cochlear implants in the basic medical insurance payment scope starting from June 1 [1][2] - The cost for patients undergoing cochlear implantation will significantly decrease from over 200,000 yuan to around 30,000 yuan, alleviating the financial burden on families of hearing-impaired patients [1][2] - The policy applies to insured individuals diagnosed with bilateral severe or profound hearing loss who cannot improve their hearing and speech understanding through hearing aids or other devices [1] Group 2 - The fifth batch of national centralized procurement for high-value medical consumables will include cochlear implants and peripheral vascular stents, with the average price for a set of cochlear implants dropping from over 200,000 yuan to approximately 50,000 yuan [2] - The Sichuan Medical Security Bureau aims to further reduce the medical expenses for insured individuals by incorporating cochlear implantation surgery and cochlear implants into the insurance payment scope [2]